NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.565
-0.095 (-5.72%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close1.660
Open1.660
Bid0.000 x 900
Ask0.000 x 1000
Day's Range1.565 - 1.670
52 Week Range1.250 - 4.800
Volume10,164
Avg. Volume19,000
Market Cap26.745M
Beta (3Y Monthly)-2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.373
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.69
Trade prices are not sourced from all markets
  • Business Wire19 days ago

    NovaBay Pharmaceuticals Names Jack McGovern Interim CEO

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that Jack McGovern has been named Interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the Company’s previous Chief Executive Officer, remains NovaBay’s Chairman and will focus on strategic growth opportunities that complement the Company’s continued organic growth.

  • Business Wire2 months ago

    NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C.

  • Business Wire2 months ago

    NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • ACCESSWIRE2 months ago

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...

  • Business Wire3 months ago

    NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7.

  • Business Wire3 months ago

    NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of whom have significant experience in promoting prescription ophthalmic products,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO.

  • Business Wire5 months ago

    NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months ended March 31, 2018 and provides a business update.

  • Business Wire5 months ago

    NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018

    NovaBay® Pharmaceuticals, Inc.  , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10.

  • Business Wire7 months ago

    NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2017 and provides a business update.

  • ACCESSWIRE7 months ago

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 20, 2018, at 4:30 ...

  • Benzinga7 months ago

    NovaBay Pharmaceuticals Q4 Earnings Outlook

    On Tuesday, NovaBay Pharmaceuticals (NYSE: NBY ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue NovaBay Pharmaceuticals EPS will likely be ...

  • Reuters8 months ago

    BRIEF-Jinzi Ham's Unit Scraps Plan To Invest In Novabay Pharma, To Boost Asset Management Subsidiary's Capital

    (Correct second bullet to boost unit’s capital by 90 mln yuan, instead of 90-100 mln yuan) March 1 (Reuters) - Jinzi Ham Co Ltd : * SAYS UNIT SCRAPS PLAN TO INVEST IN NOVABAY PHARMACEUTICALS INC * SAYS ...

  • Business Wire8 months ago

    NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 fourth quarter and full year financial results after market close on Tuesday, March 20.

  • Business Wire8 months ago

    NovaBay Pharmaceuticals Completes $6.0 Million Private Placement

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing Avenova®, a prescription product for the domestic eye care market, announces the completion of a private placement of 1.7 million shares of common stock to OP Financial Investments Limited for gross proceeds of $5,984,000.

  • Business Wire9 months ago

    NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that sales for the fourth quarter of 2017 are expected to slightly exceed $6 million, an increase of more than 49% over the prior-year period.

  • Business Wire10 months ago

    NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces stockholder approval to issue NovaBay common stock as part of a $10.32 million financing agreement with Ch-gemstone Capital Co., Ltd.

  • Business Wire10 months ago

    NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova lid and lash hygiene for the domestic eye care market, announces that it has regained compliance with NYSE American continued listing standards.

  • Capital Cube10 months ago

    ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NovaBay Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NBY-US. Comparing the performance and risk of NovaBay Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire10 months ago

    NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces the appointment of Lewis J.

  • NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube11 months ago

    NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis NovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – Johnson & Johnson, Tetraphase Pharmaceuticals, Inc., NanoViricides, Inc. and Sonoma Pharmaceuticals, Inc. (JNJ-US, TTPH-US, NNVC-US and SNOA-US) that have also reported for this period. ... Read more (Read more...)

  • Business Wire11 months ago

    NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update.

  • ACCESSWIRE11 months ago

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, ...

  • Reuters11 months ago

    BRIEF-Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder

    Nov 14 (Reuters) - Jinzi Ham Co Ltd * Says unit signs agreement to buy shares in U.S. Novabay Pharmaceuticals Inc for a combined $27.06 million * Says unit will hold 37.14 percent stake in Novabay Pharmaceuticals ...

  • Business Wire11 months ago

    NovaBay Pharmaceuticals to Hold Third Quarter 2017 Conference Call on November 14

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report third quarter 2017 financial results after market close on Tuesday, November 14.